Welcome to our dedicated page for Bioxcel Therapeutics SEC filings (Ticker: BTAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) files a range of documents with the U.S. Securities and Exchange Commission (SEC) that provide detail on its business, risks, governance, and financial condition. As a biopharmaceutical company using artificial intelligence to develop medicines in neuroscience, its SEC filings are a key source for understanding the status of IGALMI (dexmedetomidine) sublingual film, the BXCL501 clinical program, and broader pipeline and corporate activities.
On this page, you can review BioXcel Therapeutics’ current and historical SEC filings, including annual and quarterly reports that discuss its operating losses, funding needs, indebtedness, and going‑concern considerations, as well as risk factors related to IGALMI, BXCL501, BXCL502, BXCL701, and BXCL702. Form 8‑K filings capture material events such as positive topline data from the SERENITY At‑Home Pivotal Phase 3 trial, correlation study results, updates on the timing of a planned supplemental New Drug Application (sNDA) for IGALMI label expansion to at‑home use, financing transactions under an at‑the‑market equity program, and Nasdaq listing compliance notices.
Proxy materials, such as the company’s definitive proxy statement on Schedule 14A, provide information on director elections, advisory votes on executive compensation, auditor ratification, and proposals like a reverse stock split authorization to help maintain Nasdaq listing requirements. These documents also describe the board structure, committee responsibilities, and stockholder voting outcomes.
Stock Titan enhances access to these filings with AI‑powered summaries that explain complex sections in plain language, highlight key points from lengthy reports, and help users quickly locate disclosures on topics such as clinical program updates, capital structure changes, or governance matters. Real‑time integration with the SEC’s EDGAR system allows new filings, including 10‑K annual reports, 10‑Q quarterly reports, 8‑K current reports, and any Form 4 insider transaction filings, to appear promptly with concise AI insights. This makes it easier for investors, analysts, and other interested readers to follow how BioXcel Therapeutics’ regulatory, clinical, and financial profile evolves over time.
BioXcel Therapeutics, Inc. filed a Form 8-K stating that it issued a press release with its financial results for the three months ended September 30, 2025 and a business update. The press release is attached as Exhibit 99.1 and is incorporated by reference for those details.
The company notes that the information in this Form 8-K under Item 2.02, including Exhibit 99.1, is being furnished rather than filed under securities laws, which affects how it is treated for certain legal purposes.
BioXcel Therapeutics announced a scientific poster presentation on BXCL501, a sublingual dexmedetomidine film for treating agitation associated with bipolar disorder or schizophrenia in the home setting. The Phase 3 study poster was presented at the Neuroscience Education Institute Conference on November 7, 2025 by Dr. Leslie Citrome.
The poster is furnished as Exhibit 99.1 and incorporated by reference. This 8-K provides visibility into the ongoing clinical program but does not detail trial results or financial terms.
BioXcel Therapeutics (BTAI) director David J. Mack reported the vesting and settlement of 1,694 shares of Common Stock on 10/31/2025 from previously granted RSUs. Following the transaction, he beneficially owned 20,317 shares, held directly.
The RSUs were part of a grant made on November 21, 2024, totaling 20,317 RSUs, scheduled to vest in twelve equal monthly installments beginning November 30, 2024, subject to continued service as a Director.
BioXcel Therapeutics (BTAI) filed preliminary proxy materials for its 2025 annual meeting. Stockholders will vote on: electing three Class I directors (June Bray, Sandeep Laumas, M.D., and David Mack), ratifying Ernst & Young LLP as auditor for 2025, an advisory say‑on‑pay vote, authorizing a reverse stock split within 12 months if the Board determines it is necessary to regain compliance with Nasdaq’s minimum bid price requirement, and a related adjournment proposal.
The meeting is scheduled for December 12, 2025 at 9:00 a.m. ET and will be held virtually at www.virtualshareholdermeeting.com/BTAI2025. The record date is October 31, 2025. The Board recommends voting FOR all proposals. The proxy notes the company is currently in compliance with Nasdaq’s bid price rule but seeks flexibility should conditions change.
BioXcel Therapeutics (BTAI) updated its regulatory timeline, stating it now expects to complete submission of a supplemental New Drug Application (sNDA) for an IGALMI® label expansion early in the first quarter of 2026.
The filing highlights two recently completed studies that will anchor the sNDA package: the SERENITY At-Home pivotal Phase 3 safety trial for agitation associated with bipolar disorders or schizophrenia, which delivered positive topline safety and exploratory efficacy data in August 2025, and an October 2025 correlation study that also reported positive results. IGALMI® is currently FDA‑approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings, and the planned sNDA seeks to expand use to at‑home settings.
BioXcel Therapeutics (BTAI) announced positive correlation results linking the patient/caregiver-rated mCGI-S scale with the clinician-rated PEC from the SERENITY At Home program, supporting its planned supplemental NDA in the first quarter of 2026.
The prospective, open-label, in-clinic study in 33 patients showed strong, statistically significant correlations between PEC and mCGI-S (ρ=0.89; p<0.0001 for patients and ρ=0.88; p<0.0001 for informants). No serious adverse events were reported, and the safety profile remains consistent with the IGALMI® label.
Multiple Millennium-related entities report passive stakes in BioXcel Therapeutics, Inc. Integrated Core Strategies (US) LLC reports beneficial ownership of 1,026,054 shares and Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 1,028,053 shares, representing 5.2% of the outstanding common stock for each reporting person. The filing is submitted on Schedule 13G, indicating the holders state their position is passive and not intended to influence control of the issuer. The filing includes a joint filing agreement among the reporting parties.
BioXcel Therapeutics insider activity: Vimal Mehta, CEO and President and a director, reported two small acquisitions of common stock and corresponding restricted stock units in mid-September 2025. On 09/14/2025 he received 163 RSUs (vesting contingent) and 163 shares were recorded as acquired; on 09/15/2025 he received 219 RSUs and 219 shares were recorded as acquired. Following these transactions Mr. Mehta directly beneficially owned 20,493 shares. He also discloses indirect ownership of 480,343 shares held of record by BioXcel LLC, of which he is a manager, and one shareholding is reported as held by spouse.
Richard I. Steinhart, Chief Financial Officer of BioXcel Therapeutics, Inc. (BTAI), reported the acquisition of shares from vesting restricted stock units. On 09/14/2025 he received 163 shares upon vesting of RSUs and on 09/15/2025 he received 317 shares, increasing his direct beneficial ownership by those amounts. The RSUs were originally granted on March 14, 2022 (521 RSUs) and March 15, 2023 (562 RSUs) with staged vesting schedules tied to continued employment. The transactions were reported on a Form 4 signed 09/16/2025.
Javier Rodriguez, identified as Chief Legal Officer, Senior Vice President and Corporate Secretary of BioXcel Therapeutics, Inc. (BTAI), filed a Form 4 reporting transactions on September 14, 2025 and September 15, 2025. The filing discloses restricted stock unit activity tied to two prior grants: 521 RSUs awarded on March 14, 2022, and 562 RSUs awarded on March 15, 2023, each granted with time-based vesting schedules.
The tables show derivative and non-derivative entries reflecting 33 and 35 underlying shares associated with the reported transactions and list the number of vested RSU shares as 163 and 317 respectively in the derivative-security section. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on September 16, 2025.